Search Bar & Filters
Found 73 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are establishing a large-scale, integrated screening cohort for nasopharyngeal carcinoma NPC, focusing on a population from South China where the disease is more common. This cohort will collect detailed epidemiological information including demographics, lifestyle, dietary habits, and environmental factors. The study also includes creating a biobank with blood, tissue fluid, and swab samples to analyze Epstein-Barr virus EBV markers, tumors, and genetic data. Clinical examination data such as nasopharyngoscopy, imaging, and pathology will be gathered to build a comprehensive data platform for NPC research. Participants aged 30 to 69 will complete detailed questionnaires and provide biological samples for various tests, including EBV antibody and DNA testing, as well as genetic sequencing. Those identified as high-risk through screening will undergo additional clinical exams like nasopharyngoscopy and head and neck MRI to confirm diagnosis and guide treatment. The study aims to develop and improve screening strategies, explore NPC risk factors and molecular mechanisms, and investigate prevention and treatment approaches including lifestyle changes and minimally invasive therapies. Participants will be followed regularly over many years with data collected at screening, 3 years, and 10 years after. The study will monitor NPC prevalence, incidence, and mortality rates, along with overall death rates. This long-term follow-up supports understanding of NPC risk factors and outcomes. The project aims to create an open, shared, multi-source data platform to support ongoing research and improve NPC prevention, screening, and treatment strategies.
Actively Recruiting
Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating TQB3107, a targeted inhibitor designed to induce cell death and stop tumor growth, in patients with advanced cancers. This Phase I clinical trial aims to assess the safety and tolerability of TQB3107 tablets, determine dose-limiting toxicities, find the maximum tolerated dose, and recommend a dose for future Phase II studies. Participants receive TQB3107 tablets following one of two dosing schedules either daily for five consecutive days each week with a two-day break per 28-day cycle, or intermittent dosing every 28 days. The study begins with an initial single fasting dose followed by a seven-day observation before continuing the dosing cycles. This design allows researchers to monitor participants closely during the first cycle to assess safety and dosing effects. During the study, participants will have regular assessments including pharmacokinetic blood sampling at multiple time points to measure drug levels, and evaluations of dose-limiting toxicities and maximum tolerated dose at the end of the first 28-day cycle. Longer-term outcomes such as response rates, disease control, progression-free survival, and overall survival will be followed for up to three years. Participants are monitored for up to 24 months for recommended dosing and safety, with comprehensive evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are conducting a multicenter, nonrandomized, open-label Phase III clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ICP-723 in patients with solid tumors. The study focuses on patients with surgically unresectable locally advanced or metastatic solid tumors, including primary central nervous system tumors. This trial aims to better understand how ICP-723 behaves in the body and its safety profile during treatment. Participants will receive ICP-723, a white, round, uncoated tablet, as the investigational drug. The study includes adolescent participants aged 12 to under 18 years and adults aged 18 years and older. The trial involves monitoring treatment-emergent adverse events for up to 12 months and determining the maximum tolerated dose within the first two months. Secondary measures include peak drug concentration and objective response rate within specified time frames. During the study, participants will undergo evaluations of safety and tolerability, including assessments of adverse events and pharmacokinetic measurements. Measurable tumor lesions will be monitored according to established criteria. Patients will need to agree to use effective birth control methods if of childbearing potential and comply with visit schedules and treatment regimens. The total participation period includes follow-up for safety and treatment response, with data collected up to 12 months.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Healthy Volunteer
Chronic kidney disease CKD involves damage to the kidneys structure or function and affects a significant portion of the population in China, with a prevalence of 10.8%. CKD not only leads to severe kidney failure requiring treatments like dialysis but also raises the risk of cardiovascular diseases, placing a heavy burden on individuals and the healthcare system. This research aims to improve understanding of CKD occurrence, progression, treatment, prognosis, and risk factors in the Chinese population through a large-scale, real-world observational study. The study is a multi-center, prospective observational registry involving participants from various centers across mainland China. It collects and integrates standardized data to efficiently analyze CKD patterns and outcomes. The study includes both CKD patients and individuals with risk factors such as hypertension, diabetes, or hyperlipidemia, as well as healthy participants, to allow broad representation and subgroup analysis. The study is designed to cover a large sample size and account for potential loss to follow-up. Participants will be observed over up to 5 years to monitor the development of CKD in non-CKD individuals and the progression of disease in those with CKD. Researchers will track changes in kidney function, albuminuria levels, and composite endpoints including disease progression and mortality. Data collection includes clinical assessments and laboratory measurements to evaluate disease markers and outcomes. The study offers long-term monitoring to better understand CKD dynamics and inform prevention and control strategies.
Actively Recruiting
Researchers are studying a new mucosal contouring method to predict radiation-induced oropharyngeal mucositis in patients with nasopharyngeal carcinoma NPC. This condition, which causes swallowing-induced breakthrough pain, greatly affects patients quality of life during radiotherapy. Previous prediction models using oral cavity or mucosa surface contouring were not satisfactory, so this study aims to further evaluate a method based on mucosal areas linked to breakthrough pain in a real-world, multicenter observational setting. This observational study will follow patients with locally advanced NPC undergoing radical radiotherapy or chemoradiotherapy. The study focuses on assessing how well the mucosal delineation method predicts the occurrence and severity of oropharyngeal mucositis by tracking swallowing-induced breakthrough pain. There are no investigational treatments involved instead, patients are observed and data is collected during their standard care. Participants will have their oral or oropharyngeal mucositis severity and swallowing pain recorded continuously throughout their treatment. Researchers will analyze the predictive models performance by measuring accuracy, sensitivity, specificity, and other statistical values over up to three years. The study will help improve risk assessment and early intervention for mucositis in NPC patients, with all data collected during their regular clinical visits.
1-10 of 73
1